Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is โน387.17. In 2025 the company made an earnings per share (EPS) of โน337.15 an increase over its 2024 EPS that were of โน310.78.